Search

Your search keyword '"Berkkan, Metehan"' showing total 2 results
Start Over Author "Berkkan, Metehan" Topic acute renal failure
2 results on '"Berkkan, Metehan"'

1. The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis.

Author

Kanbay, Mehmet, Copur, Sidar, Siriopol, Dimitrie, Yildiz, Abdullah Burak, Berkkan, Metehan, Popa, Raluca, Hasbal, Nuri Baris, Ortiz, Alberto, and Perazella, Mark A

Subjects
IMMUNE checkpoint inhibitors, ACUTE kidney failure, CANCER prognosis, IPILIMUMAB, CANCER-related mortality, CANCER treatment
Abstract

Background Immune checkpoint inhibitors (ICPIs) are a novel therapeutic approach to cancer treatment that have changed the landscape of cancer therapy but also have some considerable drawbacks. Acute kidney injury (AKI) is one of these potential complications that may have effects on patient outcomes. In this review, we assessed the effect of AKI on mortality outcomes in cancer patients receiving this immunotherapy. Methods We performed a systematic review and meta-analysis of prospective, retrospective, randomized and non-randomized studies, which examined the effects of AKI in cancer patients receiving immune checkpoint inhibitors. We searched through PubMed, Medline, Web of Science, Scopus and Cochrane Library databases. Results Seven studies were included in the final analysis, with a total number of patients of 761. Overall, the risk of death was higher in patients that developed AKI during ICPI treatment [hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.05–1.92, P  = 0.02; heterogeneity χ2 = 11.68, I2 = 66%, P  = 0.02] compared with patients that did not develop AKI. In addition, there was a trend to a better survival in those with less severe AKI patients compared with those with more severe AKI (HR 1.35, 95% CI 0.99–1.83, P  = 0.05). Lastly, it was seen that patients with persistent kidney dysfunction (non-recovery) had an increased risk for all-cause mortality (HR 2.93, 95% CI 1.41–6.08, P  = 0.004; heterogeneity χ2 = 0.53, I2 = 0%, P  = 0.47). Conclusions Development of AKI in patients with cancer receiving immune checkpoint inhibitors is associated with increased risk of mortality. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

2. The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis

Author

Kanbay, Mehmet (ORCID 0000-0002-1297-0675 & YÖK ID 110580), Çöpür, Sidar (ORCID 0000-0003-0190-2746 & YÖK ID 368625), Yıldız, Abdullah Burak, Berkkan, Metehan, Hasbal, Nuri Barış, Siriopol, Dimitrie, Popa, Raluca, Ortiz, Alberto, Perazella, Mark A., Koç University Hospital, and School of Medicine

Subjects
Acute kidney injury, Acute renal failure, Immune checkpoint inhibitors, Immunotherapy, Nephrotoxicity, Urology and nephrology
Abstract

Lay summary: immune checkpoint inhibitors are a novel therapeutic approach to cancer treatment that have changed the landscape of cancer therapy but also have some considerable drawbacks. Acute kidney injury (AKI) is one of these potential complications that may have effects on patient outcomes. In this review, development of AKI in patients with cancer receiving immune checkpoint inhibitors is associated with increased risk of mortality. Background: immune checkpoint inhibitors (ICPIs) are a novel therapeutic approach to cancer treatment that have changed the landscape of cancer therapy but also have some considerable drawbacks. Acute kidney injury (AKI) is one of these potential complications that may have effects on patient outcomes. In this review, we assessed the effect of AKI on mortality outcomes in cancer patients receiving this immunotherapy. Methods: we performed a systematic review and meta-analysis of prospective, retrospective, randomized and non-randomized studies, which examined the effects of AKI in cancer patients receiving immune checkpoint inhibitors. We searched through PubMed, Medline, Web of Science, Scopus, and Cochrane Library databases. Results: seven studies were included in the final analysis, with a total number of patients of 761. Overall, the risk of death was higher in patients that developed AKI during ICPI treatment [hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.05-1.92, P = 0.02; heterogeneity chi(2) = 11.68, I-2 = 66%, P = 0.02] compared with patients that did not develop AKI. In addition, there was a trend to a better survival in those with less severe AKI patients compared with those with more severe AKI (HR 1.35, 95% CI 0.99-1.83, P = 0.05). Lastly, it was seen that patients with persistent kidney dysfunction (non-recovery) had an increased risk for all-cause mortality (HR 2.93, 95% CI 1.41-6.08, P = 0.004; heterogeneity chi(2) = 0.53, I-2 = 0%, P = 0.47). Conclusions: development of AKI in patients with cancer receiving immune checkpoint inhibitors is associated with increased risk of mortality., NA

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results